Show simple item record

dc.contributor.authorHauber, Ilonaen_US
dc.contributor.authorHofmann-Sieber, Helgaen_US
dc.contributor.authorChemnitz, Janen_US
dc.contributor.authorDubrau, Daniloen_US
dc.contributor.authorChusainow, Janeten_US
dc.contributor.authorStucka, Rolfen_US
dc.contributor.authorHartjen, Philipen_US
dc.contributor.authorSchambach, Axelen_US
dc.contributor.authorZiegler, Patricken_US
dc.contributor.authorHackmann, Karlen_US
dc.contributor.authorSchröck, Evelinen_US
dc.contributor.authorSchumacher, Udoen_US
dc.contributor.authorLindner, Christophen_US
dc.contributor.authorGrundhoff, Adamen_US
dc.contributor.authorBaum, Christopheren_US
dc.contributor.authorManz, Markus G.en_US
dc.contributor.authorBuchholz, Franken_US
dc.contributor.authorHauber, Joachimen_US
dc.date.accessioned2014-03-10T20:34:21Z
dc.date.issued2013en_US
dc.identifier.citationHauber, I., H. Hofmann-Sieber, J. Chemnitz, D. Dubrau, J. Chusainow, R. Stucka, P. Hartjen, et al. 2013. “Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice.” PLoS Pathogens 9 (9): e1003587. doi:10.1371/journal.ppat.1003587. http://dx.doi.org/10.1371/journal.ppat.1003587.en
dc.identifier.issn1553-7366en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11878944
dc.description.abstractStable integration of HIV proviral DNA into host cell chromosomes, a hallmark and essential feature of the retroviral life cycle, establishes the infection permanently. Current antiretroviral combination drug therapy cannot cure HIV infection. However, expressing an engineered HIV-1 long terminal repeat (LTR) site-specific recombinase (Tre), shown to excise integrated proviral DNA in vitro, may provide a novel and highly promising antiviral strategy. We report here the conditional expression of Tre-recombinase from an advanced lentiviral self-inactivation (SIN) vector in HIV-infected cells. We demonstrate faithful transgene expression, resulting in accurate provirus excision in the absence of cytopathic effects. Moreover, pronounced Tre-mediated antiviral effects are demonstrated in vivo, particularly in humanized Rag2−/−γc−/− mice engrafted with either Tre-transduced primary CD4+ T cells, or Tre-transduced CD34+ hematopoietic stem and progenitor cells (HSC). Taken together, our data support the use of Tre-recombinase in novel therapy strategies aiming to provide a cure for HIV.en
dc.language.isoen_USen
dc.publisherPublic Library of Scienceen
dc.relation.isversionofdoi:10.1371/journal.ppat.1003587en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784474/pdf/en
dash.licenseLAAen_US
dc.titleHighly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Miceen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalPLoS Pathogensen
dash.depositing.authorSchambach, Axelen_US
dc.date.available2014-03-10T20:34:21Z
dc.identifier.doi10.1371/journal.ppat.1003587*
dash.authorsorderedfalse
dash.contributor.affiliatedSchambach, Axel


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record